Advertisement


Andrew D. Zelenetz, MD, on CLL: Emerging Treatments

2016 ASH Annual Meeting & Exposition

Advertisement

Andrew D. Zelenetz, MD, of the Memorial Sloan Kettering Cancer Center, discusses novel treatments for chronic lymphocytic leukemia, touching specifically on the Gilead 115 trial.



Related Videos

Leukemia
Survivorship

Smita Bhatia, MD, MPH, and Jessica Wu, BA, on CML: A Report From the Bone Marrow Transplant Survivor Study

Smita Bhatia, MD, MPH, and Jessica Wu, BA, both of the University of Alabama at Birmingham, discuss long-term morbidity and mortality experienced by chronic myeloid leukemia patients after allogeneic hematopoietic cell transplantation (Abstract 823).

Lymphoma

Umberto Vitolo, MD, and Sagar Lonial, MD, on DLBCL: Final Results From the GOYA Trial

Umberto Vitolo, MD, of Città della Salute e della Scienza Hospital and University, and Sagar Lonial, MD, of Emory University, discuss study findings on obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (Abstract 470).

Leukemia

Martin Schrappe, MD, on Childhood ALL: Study Results on Reducing Treatment Burden (German Language Version)

Martin Schrappe, MD, of Christian-Albrechts University Kiel, discusses in German study findings on reduced intensity delayed intensification in standard-risk patients defined by minimal residual disease in childhood acute lymphoblastic leukemia (Abstract 4).

Lymphoma

Steven Le Gouill, MD, PhD, on Mantle Cell Lymphoma: Final Results From the LyMa Trial

Steven Le Gouill, MD, PhD, of Nantes University Hospital and INSERM, discusses study findings from the Lysa/Goelams Group on rituximab maintenance after autologous stem cell transplantation in younger patients with mantle cell lymphoma (Abstract 145).

Hematologic Malignancies
Issues in Oncology

Marie Bleakley, MD, PhD, on GVHD: Reducing Rates and Increasing Survival

Marie Bleakley, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses data on using naive T-cell depletion of peripheral blood stem cells, which led to very low rates of chronic graft-vs-host-disease and high survival (Abstract 668).

Advertisement

Advertisement




Advertisement